{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Skeletal related events were defined as pathological fractures, radiation to bone, surgery to bone, or fractures requiring stabilization, confirmed by imaging. Participants were counted once if they experienced at least one skeletal related event during the 1 year follow up period.","groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"OG000","title":"Denosumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis includes participants who completed the 1 year assessment period.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Proportion of Participants With Skeletal Related Events","type":"SECONDARY","unitOfMeasure":"Participants"}